In Alternative Views, Private Equity Wire® goes behind closed doors with those in the know to get the latest on private markets. In this episode we discuss investment in therapeutics with Ksenija Pavletic, general partner and chief commercial officer at biopharma-focused firm Jeito Capital.
Jeito recently closed its second fund at $1.2bn, which the firm says is the largest raise ever achieved by a fully independent European fund dedicated to biopharma.
Pavletic discusses the segments of biopharma which are most attractive (0:49); investing in R&D vs commercialisation (2:58); why inefficiency and the patent cliff is driving Big Pharma to acquire smaller companies (6:03); and the funding shortfall in European biopharma (10:12).
